Screener Summaries Updates Institutions Sign In More Updates › Other Events › HCWB Other Events · Jul 1, 2026
HCW Biologics Inc. reported the settlement and extinguishment of $2.8 million in disputed accounts payable, including… HCWB HCW Biologics Inc.
HCW Biologics Inc. reported the settlement and extinguishment of $2.8 million in disputed accounts payable, including a $1.1 million lien satisfaction from B&I Contractors, Inc. and the full payment of a $1.2 million settlement with EirGenix, Inc. regarding manufacturing costs. HCW Biologics Inc. is a biotechnology company focused on the development and manufacturing of biologics.
More from HCW Biologics Inc. HCW Biologics closes $10M secured debt financing, including $3M upfront Nov 5, 2026 HCW Biologics sells units for $1.5M in private placement subject to Nasdaq stockholder approval Sep 24, 2026 HCW Biologics Inc. entered into an Exclusive Distribution Agreement with Akron Biotech on September 4, 2026, for the… Sep 8, 2026 HCW Biologics Inc. reported financial results for the quarter ended June 30, 2026, including a net loss of $5.2… Aug 14, 2026 HCW Biologics Inc. announced on August 10, 2026, that its Audit Committee concluded previously issued unaudited… Aug 14, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
